Medtronic Plc (MDT) concluded trading on Wednesday at a closing price of $81.24, with 7.51 million shares of worth about $610.41 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -4.13% during that period and on Wednesday the price saw a gain of about 0.07%. Currently the company’s common shares owned by public are about 1.28B shares, out of which, 1.28B shares are available for trading.
Stock saw a price change of -5.94% in past 5 days and over the past one month there was a price change of -3.33%. Year-to-date (YTD), MDT shares are showing a performance of 1.70% which decreased to -0.17% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $75.96 but also hit the highest price of $96.25 during that period. The average intraday trading volume for Medtronic Plc shares is 7.83 million. The stock is currently trading -3.21% below its 20-day simple moving average (SMA20), while that difference is down -4.64% for SMA50 and it goes to -6.82% lower than SMA200.
Medtronic Plc (NYSE: MDT) currently have 1.28B outstanding shares and institutions hold larger chunk of about 85.90% of that.
The stock has a current market capitalization of $104.19B and its 3Y-monthly beta is at 0.80. PE ratio of stock for trailing 12 months is 22.46, while it has posted earnings per share of $3.62 in the same period. Its PEG reads 4.03 and has Quick Ratio of 1.42 while making debt-to-equity ratio of 0.59. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MDT, volatility over the week remained 2.22% while standing at 1.59% over the month.
Stock’s fiscal year EPS is expected to rise by 1.24% while it is estimated to increase by 7.96% in next year. EPS is likely to grow at an annualized rate of 5.58% for next 5-years, compared to annual growth of 0.37% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Citigroup on March 04, 2025 offering a Buy rating for the stock and assigned a target price range of between $92 and $107 to it. Coverage by RBC Capital Mkts stated Medtronic Plc (MDT) stock as an Outperform in their note to investors on October 10, 2024, suggesting a price target of $105 for the stock. On August 21, 2024, Oppenheimer Reiterated their recommendations, while on August 15, 2024, UBS Upgrade their ratings for the stock with a price target of $90. Stock get a Hold rating from Stifel on August 14, 2024.
